U.S. Gas Utilities Stock News

In the first quarter of 2026, COMPASS Pathways reported net income of US$91.2 million, or US$0.71 per share, and announced U.S. FDA acceptance of a rolling New Drug Application and a National Priority Review Voucher for its COMP360 psilocybin therapy in treatment-resistant depression. This combination of an accounting-driven swing to profitability and accelerated regulatory review for COMP360 marks a key moment for COMPASS Pathways’ shift from pure R&D focus toward potential commercial...

VEON (NasdaqGS:VEON) has opened 2026 with Q1 numbers that put the focus squarely on earnings quality, reporting US$1.2 billion in revenue and basic EPS of US$1.42, while trailing twelve month EPS sits at US$7.65 on revenue of US$4.6 billion. Over recent quarters the company has seen revenue move from US$998 million in Q4 2024 to US$1.03 billion in Q1 2025, US$1.09 billion in Q2 2025 and US$1.20 billion in Q1 2026, with quarterly EPS ranging from a loss of US$2.00 in Q3 2025 to US$8.50 in Q2...

Why EnerSys is back in focus after its latest growth update EnerSys (ENS) has drawn fresh attention after outlining plans to expand in data centers and defense, including reallocating manufacturing capacity and steering its Greenville lithium facility toward drones and soldier power systems. See our latest analysis for EnerSys. The recent communications on AI infrastructure and defense electrification sit alongside very strong momentum, with a 30 day share price return of 20.45%, a year to...

QuickLogic (QUIK) opened Q1 2026 with revenue of about US$5.1 million and a basic EPS loss of US$0.13, setting the tone for another quarter where the top line and per share results remain firmly in focus for investors who track the stock through earnings season. Over the past year, the company has reported quarterly revenue in a range of roughly US$2.0 million to US$5.7 million, while basic EPS has ranged from a small profit of about US$0.01 per share to a quarterly loss of about US$0.24 per...

Perella Weinberg Partners recently reported first-quarter 2026 results showing net income of US$1.49 million, down sharply from US$17.34 million a year earlier, while also affirming a quarterly dividend of US$0.07 per Class A share payable in June. Alongside the weaker quarter, the firm expanded Chief Financial Officer Alexandra Gottschalk’s remit to include Chief Operating Officer, highlighting a tighter focus on operational execution as management cited longer timelines to complete complex...

Hasbro’s Q1 2026 earnings in focus Hasbro (HAS) opened 2026 with Q1 revenue of US$1,000.2 million and basic EPS of US$1.41, setting a clear snapshot of the business against a current share price of US$95.65. Over recent quarters the company has seen revenue move from US$887.1 million in Q1 2025 to US$1,000.2 million in Q1 2026, while basic EPS shifted from US$0.71 to US$1.41 over the same period. This gives investors a clearer look at how the top line and per share earnings are tracking. With...

Lineage Cell Therapeutics (LCTX) opened 2026 with Q1 revenue of US$1.7 million and a basic EPS loss of US$0.02, as net income excluding extraordinary items came in at a loss of US$4.8 million. The company has seen quarterly revenue move between US$1.5 million and US$6.6 million over the past year, while EPS has ranged from a loss of around US$0.13 per share to a small profit of US$0.00 per share, presenting a mixed picture regarding the path toward better margins. For investors, the latest...

Espey Mfg. & Electronics (ESP) has reported another solid set of Q3 2026 numbers, with revenue of about US$11.4 million and basic EPS of roughly US$1.03, supported by trailing 12 month EPS of US$3.95 on revenue of around US$42.2 million. The company has seen quarterly revenue range between US$9.1 million and US$13.6 million over the past six periods, while basic EPS has moved between US$0.66 and US$1.10. This sets up the latest quarter against a backdrop of higher trailing earnings growth and...

Capital raising moves put GH Research in focus GH Research (GHRS) has filed a universal shelf registration of up to US$400 million across multiple securities, alongside a US$200 million at-the-market follow-on equity program for its ordinary shares. See our latest analysis for GH Research. The capital raising plans come after a strong run, with the share price at US$21.88 and a 30 day share price return of 33.9%. The 1 year total shareholder return of 119.24% and 3 year total shareholder...

MaxCyte (NasdaqGS:MXCT) opened Q1 2026 with revenue of US$9.7 million and a basic EPS loss of US$0.04, while trailing 12 month figures show revenue of US$32.3 million and a basic EPS loss of US$0.37. The company has seen quarterly revenue move from US$10.4 million in Q1 2025 to US$9.7 million in Q1 2026, with net income moving from a loss of US$10.3 million to a loss of US$4.8 million over the same period. These figures frame the discussion for investors who are focused on how margins develop...

Costamare Bulkers Holdings (NYSE:CMDB) has opened 2026 with Q1 revenue of US$111.5 million, basic EPS of US$0.41 and net income of US$9.9 million, setting a clearer profit picture against a share price of US$19.02. The company has previously reported quarterly revenue figures ranging from US$222.9 million to US$318.9 million and a mix of positive and loss making EPS and net income results, so this quarter slots into a track record that already includes periods of pressure on earnings quality...

AI spending is no longer just a race to build the biggest models; it is increasingly about which companies can turn that investment into real earnings. With inflation pressures touching everything from fuel to freight, and central banks keeping rates higher for longer, cash generation and pricing power matter more than ever. The Profitable AI Stocks screener focuses on businesses already using AI to support profits rather than just promises. This article highlights 3 stocks from that list...

If you are wondering whether CF Industries Holdings at US$122.97 is still offering value after its run, the next sections walk through what the current price may be baking in. The stock has returned 3.6% over the last 7 days, 3.4% over the past month, 53.5% year to date and 45.1% over the last year, so recent performance is front of mind for many investors assessing what comes next. Recent news coverage has focused on CF Industries Holdings as a key player in the fertilizers and chemicals...

CareTrust REIT (CTRE) raised its 2026 earnings guidance and shared first quarter results that showed higher revenue and net income, giving investors fresh data on how the healthcare focused landlord is currently performing. See our latest analysis for CareTrust REIT. The stock has gained 15.48% year to date on a share price basis to $41.93, while the 1 year total shareholder return of 52.47% and 3 year total shareholder return above 7x suggest momentum has been strong over multiple...

If you are wondering whether Consolidated Edison at around US$107 per share still offers fair value, you will want to see how different valuation methods line up on this stock. The share price has moved 0.7% over the last week, is down 4.1% over the last month, yet shows returns of 7.1% year to date, 8.5% over 1 year, 24.5% over 3 years and 62.7% over 5 years. This gives useful context before comparing price to fundamentals. Recent headlines have focused on Consolidated Edison in relation to...

Planet Labs PBC (NYSE:PL), through its German subsidiary, has secured a significant two-year contract with the Czech Republic's State Agricultural Intervention Fund. The agreement covers satellite imagery and AI-powered analytics to support agricultural monitoring and payments across the country. The contract is a multi-year, seven-figure national government deal that expands Planet Labs' role with European public sector agencies. Planet Labs PBC operates a fleet of Earth observation...

In May 2026, Principal Financial Group announced a new API integration with benefits administration platform Employee Navigator, allowing employees to complete evidence of insurability health questions directly within their initial benefits enrollment to streamline data sharing and speed up underwriting decisions for group benefits. This move highlights Principal’s push to simplify benefits administration for more than 90,000 small and midsize employer clients by reducing enrollment...

Earlier this week, Johnson & Johnson’s Shockwave Medical unit launched the Shockwave C2 Aero coronary intravascular lithotripsy catheter globally, offering improved deliverability, lesion crossing and repositioning for treating calcified coronary artery disease in the U.S. and Japan, with Europe and Canada to follow. This next-generation device broadens Johnson & Johnson’s intravascular lithotripsy portfolio in a complex, high-need area of cardiovascular care, reinforcing the company’s...

Nurix Therapeutics announced that CEO Arthur T. Sands will join fireside chats at major upcoming healthcare conferences and that updated efficacy and safety data for its oral BTK degrader bexobrutideg (NX-5948) in chronic lymphocytic leukemia will be presented in an oral session at the 2026 European Hematology Association Congress. The oral presentation slot and conference participation highlight growing scientific and investor attention on Nurix’s targeted protein degradation pipeline,...

Camtek (NasdaqGM:CAMT) sets the tone with Q1 2026 earnings Camtek (NasdaqGM:CAMT) opened 2026 with Q1 revenue of US$121.7 million and basic EPS of US$0.68, setting a clear marker for how the year is starting to shape up. The company has seen revenue move from US$117.3 million in Q4 2024 to US$128.1 million in Q4 2025, with basic EPS across those periods ranging from US$0.73 to US$0.78, while trailing 12 month EPS sits at US$1.05 on revenue of US$499.1 million. With a trailing net margin of...

Rising inflation worries, higher bond yields and choppy energy markets are putting pressure on weaker companies, especially those that rely heavily on cheap financing to survive. That environment can be harsh for most penny stocks, which often run out of cash before their plans get off the ground. The Elite Penny Stocks screener focuses only on companies with balance sheets that look better equipped to fund their ambitions. In this article, you will see 3 of the most interesting stocks from...

Why Trinity Capital's fresh equity raise matters after earnings Trinity Capital (TRIN) has followed its recent first quarter earnings release with a new at the market follow on equity offering of up to US$300 million in common stock. The timing links two key themes investors tend to focus on: quarterly profitability and balance sheet capacity. It also raises fresh questions about how the company might deploy additional capital against its existing tech lending and equipment financing...

Rising interest in Oklo (OKLO) is being driven by a cluster of fresh updates, including wider first quarter losses, a sizeable cash position, accelerated U.S. regulatory progress, and a new AI focused partnership with Idaho National Laboratory. See our latest analysis for Oklo. Oklo’s share price has pulled back in the very short term, with a 1 day share price return down 3.52% and a 7 day share price return down 6.43%, even after a 14.73% 30 day share price return and a very large 3 year...

Paysign, Inc. reported past first-quarter 2026 results on May 12, posting revenue of US$28.04 million and net income of US$5.44 million, with diluted EPS of US$0.09 from continuing operations. The quarter marked a shift as patient affordability programs became Paysign’s largest revenue contributor, reflecting a mix change toward higher-margin pharma offerings. We’ll now examine how this record first quarter and the rise of patient affordability as Paysign’s largest revenue stream affect its...